anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Larger portions of food elicit greater intake than smaller portions of food, particularly when foods are high in energy density (kcal/g; ED). The neural mechanisms underlying this effect remain unclear. The present study used fMRI to assess brain activation to food (higher-ED, lower-ED) and non-food (office supplies) images presented in larger and smaller (i.e., age-appropriate) amounts in 61, 7-8-year-olds (29 male, 32 female) without obesity. Larger amounts of food increased activation in bilateral visual and right parahippocampal areas compared to smaller amounts; greater activation to food amount (larger > smaller) in this cluster was associated with smaller increases in food intake as portions increased. Activation to amount (larger > smaller) was stronger for food than office supplies in primary and secondary visual areas, but, for office supplies only, extended into bilateral parahippocampus, inferior parietal cortex, and additional visual areas (e.g., V7). Activation was greater for higher-vs. lower-ED food images in ventromedial prefrontal cortex for both larger and smaller amounts of food; however, this activation extended into left lateral orbital frontal cortex for smaller amounts only. Activation to food cues did not differ by familial risk for obesity. These results highlight potentially distinct neural pathways for encoding food energy content and quantity.
Participants with HIV-1 who chose direct to injections (D2I) received the first injections of 600 mg CAB LA + 900 mg RPV LA, IM as initial loading doses at Day 1 one month, followed by second and third subsequent injections (CAB LA 600 mg + RPV LA 900 mg) at month 1 and month 3 followed by Q2M until Month 11. The participants had the option to continue the regimen in the Extension Phase.
The invention relates to a novel genital herpes vaccine and provides a human-derived codon optimized gene gD2 for coding HSV-2 glycoprotein D. The sequence of the human-derived codon optimized gene gD2 is SEQ ID NO:1. The invention further provides a gene gD2deltaUL25 formed by fusion of the gene gD2 and a truncated gene for coding HSV-2 capsid protein UL12. The sequence of the gene gD2deltaUL25 is SEQ ID NO:2. The invention further provides two recombinant adenoviruses respectively containing the two genes, a recombinant modified Ankara strain vaccinia virus, recombinant varicella-zoster virus and a preparation method of the two recombinant adenoviruses. The invention further provides application of the two genes and recombinant viruses in preparation of a medicine preparation for preventing and/or controlling diseases (such as genital herpes) caused by HSV-2. The invention further provides a combined vaccine containing an inactivated HSV-2 virus and different combinations of the recombinant viruses.
BACKGROUND: Children undergoing outpatient surgery are at risk of inadequate postoperative pain control. Methadone has a long duration of action and an intraoperative dose may provide stable analgesia throughout the postoperative period. Intraoperative methadone has been shown to improve pain control in adolescents but its use for postoperative pain in pediatric patients undergoing outpatient surgery has not been studied before. Therefore, we conducted a double-blind randomized placebo-controlled trial to investigate the effects of a single dose of intraoperative methadone in children aged less than 5 years undergoing orchiopexy for undescended testis.
METHODS: A total of 68 children were randomized to receive either methadone (0.1 mg/kg) or isotonic saline following induction of anesthesia. Exclusion criteria included preterm birth, previous scrotal surgery, and parents' inability to consent. Primary outcomes were opioid requirements (first primary outcome) and pain intensity in the post-anesthesia care unit. Secondary outcomes included episodes of desaturation and time until readiness to discharge from the post-anesthesia care unit, sleep on the first postoperative night, pain intensity, and opioid requirements at home until the evening on the first postoperative day. Follow-up was 4 days.
RESULTS: Sixty children completed the study (age, mean ± SD, 26.2 ± 13.9 months), 29 children received methadone, and 31 children received placebo. Eighteen children required opioids in the post-anesthesia care unit, five children in the methadone group (proportion = 0.17, 95% confidence interval (CI): 0.07, 0.36) compared to thirteen patients in the placebo group (0.42, 95% CI: 0.26, 0.60) (mean difference = -0.24 and 95% CI: -0.03, -0.47) (p = 0.037). Five children in the methadone group (0.17, 95% CI: 0.03, 0.31) versus ten in the placebo group (0.32, 95% CI: 0.16, 0.49) had a face, legs, activity, cry, consolability score of ≥5 in the post-anesthesia care unit (mean difference = -0.15, 95% CI: -0.36, 0.06) (p = .179). More children in the placebo group woke up due to pain the first night following surgery (seven children vs. one child). The methadone group had a longer stay in the post-anesthesia care unit. There were no differences between the two groups regarding the other secondary outcomes.
CONCLUSION: A single dose of intraoperative methadone reduces short-term postoperative opioid requirements in children after orchiopexy for nondescended testes but prolongs the duration of their stay in the post-anesthesia care unit.
Patients with metastatic CSCC: to distant sites or lymph nodes. Cemiplimab administered intravenously (IV) every 2 weeks (Q2W).
The invention relates to a composition for preventing and treating a heart cerebrovascular disease, which is prepared from the following raw materials in part by weight: 10 to 40 parts of red yeast rice, 10 to 40 parts of hawthorn leaf, 5 to 40 parts of ginkgo leaf and 5 to 40 parts of lotus leaf. The composition and a pharmaceutically acceptable vector or excipient are prepared into various preparations, which can be tablets, capsules, particles, pills, tea bags, medicinal liquor, oral liquid or other any proper formulation. The composition has the advantages of restoring consciousness and causing resuscitation, promoting blood circulation by removing blood stasis, clearing and activating the channels and collaterals, supporting the weak and restraining the powerful, regaining consciousness and reducing fainting, and adjusting the five internal organs. While the composition is orally taken, proper liquid intravenous infusion and oxygen uptake are performed; and the therapy of acupuncture on corresponding acupuncture points is matched. The best selection for treating the cerebrovascular disease is to detect and treat early. The composition for preventing and treating the heart cerebrovascular disease has the advantages of low cost, minimum pain, shortest treatment course and highest recovery rate.
OBJECTIVE: To develop an efficient and robust method based on three dimensional facial landmarks for evaluating chin region asymmetry at the soft tissue level and to compare it with the traditional mirror-overlap analysis method in order to test its availability.
METHODS: Standard symmetrical face was used for mental tubercle coordinate transformation so as to filter soft tissue three dimensional spatial angle and construct corresponding three dimensional spatial angle wireframe template. Ten patients aged 12-32 years with clinical chin region asymmetry diagnosis at the Department of Orthodontics of Peking University Hospital of Stomatology from November 2020 to November 2021 were randomly selected. Three dimensional soft tissue face scan data of the patients were collected by three dimensional face scanner and the landmark points were automatically determined by the Meshmonk non-rigid registration algorithm program, and in this way, the asymmetric three dimensional spatial angle wireframe template and corresponding spatial angle parameters were generated. Mirror-overlap analysis of face scan data was also performed in Geomagic Studio 2015 software and deviation color maps were generated. This study took mirror-overlap analysis as the gold standard method, the response rate of chin region asymmetry was eva-luated by the outcomes of the mirror-overlap analysis and three dimensional spatial angle wireframe template analysis.
RESULTS: Nine three dimensional spatial angle indicators were selected through coordinate transformation, and the response rate was calculated using mirror-overlap analysis as the gold standard method. Among these ten selected patients, the response rate of the total chin region asymmetry was 90% (9/10). Using the deviation value of mirror-overlap analysis as a reference, the response rate of chin region asymmetry in the X dimension was 86%, the response rate of chin region asymmetry in the Y dimension was 89%, and the response rate of chin region asymmetry in the Z dimension was 100%.
CONCLUSION: The three dimensional soft tissue spatial angle wireframe template proposed in this study has some feasibility in evaluating chin region asymmetry at the soft tissue level, and its ability to recognize asymmetry separately in the three dimensional direction is better than the mirror-overlap analysis method, and the indicators recognition rate still needs to be further improved.
The dystrophin protein has well-characterized roles in force transmission and maintaining membrane integrity during muscle contraction. Studies have reported decreased expression of dystrophin in atrophying muscles during wasting conditions, and that restoration of dystrophin can attenuate atrophy, suggesting a role in maintaining muscle mass. Phosphorylation of S3059 within the cysteine-rich region of dystrophin enhances binding between dystrophin and β-dystroglycan, and mimicking phosphorylation at this site by site-directed mutagenesis attenuates myotube atrophy in vitro. To determine whether dystrophin phosphorylation can attenuate muscle wasting in vivo, CRISPR-Cas9 was used to generate mice with whole body mutations of S3059 to either alanine (DmdS3059A) or glutamate (DmdS3059E), to mimic a loss of, or constitutive phosphorylation of S3059, on all endogenous dystrophin isoforms, respectively. Sciatic nerve transection was performed on these mice to determine whether phosphorylation of dystrophin S3059 could attenuate denervation atrophy. At 14 days post denervation, atrophy of tibialis anterior (TA) but not gastrocnemius or soleus muscles, was partially attenuated in DmdS3059E mice relative to WT mice. Attenuation of atrophy was associated with increased expression of β-dystroglycan in TA muscles of DmdS3059E mice. Dystrophin S3059 phosphorylation can partially attenuate denervation-induced atrophy, but may have more significant impact in less severe modes of muscle wasting.
PURPOSE: Pharmaceutical compositions for the prevention of diabetes or improvement and compositions for health functional food which include the combinations of herb medicine as an effective ingredient has more elevating effect in blood sugar control effect with the combination of lotus root, Japanese apricot and spinach compare the individual injection. CONSTITUTION: Pharmaceutical compositions for the prevention of diabetes or cure include the lotus root, Japanese apricot and spinach. Compositions for health functional food which include the combinations of herb medicine include the lotus root, Japanese apricot and spinach. The weight ratio is 10-1000 parts by weigh of the Japanese apricot and 10-1000 parts by weight of the spinach per 100 parts by weight of the lotus root. The lotus root, Japanese apricot and spinach are the crude extracts of solvent selected from a group of a pulverized product, the pulverized product filtered, a pulverized product dried, water, C1-C4 alcohol and its combinations. The forms are powders, granules, refinement, capsules, suspension, emulsion, syrup, liquid, aerosol, extract, injections, percutaneous injections or suppository. The forms are liquid, aerosol, powders, granules, refinements, capsules, pills, extracts, tea, jelly or drink. When extracts of chieves ethanol 100~0.01 microgram per milliliter are dealt, toxicity will not affect as the survival rate of 3T3-L1 whole fat cells are remained over 100% in every concentrations. [Reference numerals] (AA) Relative concentration
FIELD: biotechnology, veterinary science, microbiology. SUBSTANCE: strain of bacterium Bacillus subtilis VKM B-2250D is isolated from soil. Cells of the strain is gram-positive, they do not form capsule but form round spores and show aerobic type of respiration. Strain hydrolyses glucose, mannitol but does not ferment sucrose, inositol, sorbitol, maltose and lactose and does not produce gas in fermentation. Strain inhibits the growth of staphylococci, enteric bacilli, enterobacteria, citrobacteria and aeromonas. Strain is used as an industrial one for production of probiotic preparation "Subtilis". The preparation normalizes the function of gastroenteric tract in animals, poultry and piscine and can be used in treatment and prophylaxis of bacterial infections. Invention can be used for preparing the preparation of the probiotic group. EFFECT: strain indicated above, valuable veterinary and medicinal properties. 1 tbl, 5 ex
The proposed Post-Market Clinical Follow-up study is a Prospective, Multi-Center, Observational Study, aiming to further demonstrate the safety and effectiveness of the FemoSealTM VCS in achieving hemostasis of common femoral artery (CFA) access site in real-world subjects undergoing percutaneous endovascular procedures. 230 patients will be enrolled at up to 6 European sites. Follow-ups are scheduled at 30 days (±7 days) by hospital visit or telephone call.

The sponsor shall provide training and the necessary guidelines to assist each investigation site on the data collection in the eCRF. Each site is responsible to report the available data requested by the CIP. In order to ensure data quality, validation \& consistency, edit checks will be designed during database development. Data Management team and the study monitors will be responsible to review the data and raise queries in the eCRF. Data cleaning will be done in regular intervals specified in Data Monitoring Plan. The final clean standardised datasets will be available prior to database lock for data analysis. An audit trail logging all data entered and edited is available within the EDC system. All source documents are maintained in the hospital files ready for inspection by the Sponsor and regulatory authorities upon request. The Sponsor will inform the investigator of the time period for retaining these records as per applicable regulatory requirements.

The study will be monitored at all stages of its development by study monitors appointed by the sponsor. Study monitors are designated as Sponsor representatives and are assigned to oversee the conduct and progress of the study at each site in accordance with the Monitoring Plan established for this clinical investigation.
This proposal includes three different aspects of assessment for menthol smoking young adults. The laboratory phase includes three separate sessions of laboratory smoking through a machine designed to measure puff behavior; the EMA phase includes 21 days of monitoring smoking behavior and attitudes related to smoking when smoking one's usual brand cigarette, the assigned menthol low nicotine cigarette, and the assigned non-menthol low nicotine cigarette in the participant's natural environment. The order of administration of smoking menthol and non-menthol VLNC will be counterbalanced. There will be a 7-day wash-out period between each 7-day period of using low nicotine cigarettes. The final phase includes a virtual marketplace where participants can purchase and use the research cigarettes in the context of other available tobacco products on the market, or purchase no tobacco products at all. There will be a final assessment, over the phone or in-person, 30-days after the final study visit (at week 8), to assess tobacco use behavior and attitudes about tobacco use. Participants will be enrolled for approximately 9 weeks. Week 1 will consist of smoking one's usual brand of cigarette in the laboratory and then in their home environment for 7-days. Week 2 will consist of smoking the first very low nicotine cigarette in the home environment for 7 days and then in the laboratory. Week three will consist of a 7-day wash-out period where participants can smoke their usual brand again, as they normally would. Week 4 will consist of smoking the second very low nicotine cigarette at home for 7 days and then in the laboratory. Week 5 will consist of returning to the laboratory for a final study visit and complete a hypothetical experimental tobacco marketplace. One month (4 weeks) after the final study visit (week 9), participants will complete a 30-day follow-up of cigarette smoking and other tobacco use behavior.
Enzalutamide is an androgen receptor inhibitor. The chemical name is 4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl}-2-fluoro-N-methylbenzamide.

The molecular weight is 464.44 and molecular formula is C21H16F4N4O2S. The structural formula is:

Enzalutamide is a white crystalline non-hygroscopic solid. It is practically insoluble in water.

XTANDI is available as liquid-filled soft gelatin capsules for oral administration. Each capsule contains 40 mg of enzalutamide as a solution in caprylocaproyl polyoxylglycerides. The inactive ingredients are caprylocaproyl polyoxylglycerides, butylated hydroxyanisole, butylated hydroxytoluene, gelatin, sorbitol sorbitan solution, glycerin, purified water, titanium dioxide, and black iron oxide.

XTANDI is also available as film-coated tablets for oral administration. Each tablet contains 40 mg or 80 mg of enzalutamide. The inactive ingredients are hypromellose acetate succinate, microcrystalline cellulose, colloidal silicon dioxide, croscarmellose sodium, and magnesium stearate. The tablet film-coat contains hypromellose, talc, polyethylene glycol, titanium dioxide, and ferric oxide.
Adverse reactions of orphenadrine citrate are mainly due to the mild anti-cholinergic action of orphenadrine citrate and are usually associated with higher dosage. Dryness of the mouth is usually the first adverse effect to appear. When the daily dose is increased, possible adverse effects include tachycardia, palpitation, urinary hesitancy or retention, blurred vision, dilatation of pupils, increased ocular tension, weakness, nausea, vomiting, headache, dizziness, constipation, drowsiness, hypersensitivity reactions, pruritus, hallucinations, agitation, tremor, gastric irritation and rarely urticaria and other dermatoses. Infrequently, an elderly patient may experience some degree of mental confusion. These adverse reactions can usually be eliminated by reduction in dosage. Very rare cases of aplastic anemia associated with the use of orphenadrine tablets have been reported. No causal relationship has been established.
PROBLEM TO BE SOLVED: To provide atmoizable products sparingly making atomizing sound, capable of atomizing compositions in a sufficiently diffused state of spray feeling soft and capable of giving good feelings in use, and to provide compositions for being atomized useful for atomizable products such as a face lotion, an astringent, a tonic or the like. SOLUTION: This composition contains (A) water or a mixed solvent composed of water and an alcohol (e.g. ethanol) and (B) a surfactant (e.g. polyethylene alkyl ether). The concentration of the surfactant is not less than 0.001 wt.% (based on the whole quantity of the composition) and micelles are formed by the surfactant to reduce the luminous transmittance of the composition to 80% or lower. This atomizable product is produced by filling the composition for being atomized into a container for an atomizer.
Patients assigned to this group are treated with the triple therapy with vonoprazan 20 mg bid, clarithromycin 200 mg bid and amoxicillin 750 mg bid for 1 week as the first line therapy or the triple therapy with vonoprazan 20 mg bid, metronidazole 250 mg bid and amoxicillin 750 mg bid for 1 week as the second line therapy. The eradication rates attained with these regimens are measured.
After induction, patients will be received saline bolus, then will be administered saline infusion intraoperatively. Anesthesia will be maintained with %4-6 desflurane and 0,25-0,5 microgram/dk/min remifentanil.
The invention relates to a Chinese traditional medicine composition for improving the limb iciness condition. The Chinese traditional medicine composition for improving the limb iciness condition includes, by weight, 5-8 parts of crude lateral roots of aconite, 5-6 parts of dried ginger and 5-10 parts of folium artemisiae argyi. A preparing method for the Chinese traditional medicine composition for improving the limb iciness condition includes the steps that the raw materials are prepared by weight, cleaned and placed in a drying oven of 60-70 DEG C to be dried; the dried raw materials are porphyrized and screened through a 100-mesh sieve. The materials of the Chinese traditional medicine composition for improving the limb iciness condition are matched with and supplement one another. The Chinese traditional medicine composition for improving the limb iciness condition has the efficacies of dredging the channels, eliminating dampness and dispelling iciness, and effectively relieves and improves the limb iciness condition. The Chinese traditional medicine composition has no toxic substance or any side effect, and is easy to prepare, economical and practical.
Primary aldosteronism (PA) is the most common form of secondary hypertension, accounting for more than 5% of the general hypertensive cases and 17-20% of resistant hypertension.The most common PA subtype is bilateral idiopathic hyperaldosteronism (IHA), and medical therapy with mineralocorticoid receptor antagonists (MRAs) is recommended for these patients.The clinical studies showed that PA patients had more cardiovascular events than patients with essential hypertension independent of blood pressure, and PA patients with higher plasma aldosterone levels had a higher cardiovascular risk. However, MRAs are unable to reduce the level of plasma aldosterone. Moreover, the undesirable adverse effects of MRAs also limit their wide application, particularly in men.

Superselective adrenal artery embolization (SAAE) has been used as a minimally invasive alternative for the treatment of adrenal tumors. The clinical efficacy of SAAE has been proved by a number of clinical studies. Since the efficacy and safety of SAAE was justified by the treatment of adrenal tumors and APA, we hypothesized that SAAE might cause a significant reduction of blood pressure in cases of hypertension caused by bilateral IHA. Here, we intend to conduct a prospective cohort study to demonstrate the efficacy and safety of SAAE for bilateral IHA with a one-month follow-up.